Current Trends in Diagnosis and Management of Cardiac Amyloidosis

Esplin, Brandt L.; Gertz, Morie A.

doi:10.1016/j.cpcardiol.2012.11.002

Cited by 59 publications

(77 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The present findings support earlier studies [45,46] reporting that although pharmacotherapy is readily available and a preferred firstline of RCM treatment, RCM has a general ominous prognosis due to restrictive hemodynamics leading to pulmonary hypertension and progressive heart failure, and a demonstrated poor tolerance to medical therapy [45,46]. Moreover, RCM has one of the leading recorded rates of sudden cardiac death of up to 70% in the fifth year in diagnosed cardiomyopathies [45].…”

Section: Discussionsupporting

confidence: 89%

“…Prognosis varies depending on the underlying cause with RCM in the context of cardiac amyloidosis showing worse prognosis [45]. RCM is associated with poor tolerance of medication for cardiovascular conditions and sometimes heart transplantation, which has otherwise had favorable long-term prognosis for other forms of cardiomyopathies such as dilated and hypertrophic cardiomyopathy [46]. However, recent advances made on RCM diagnosis and prompt clinical management have promised a favorable prognosis [47].…”

Section: Status Of Prognosismentioning

confidence: 99%

See 1 more Smart Citation

Restrictive cardiomyopathy: A review of literature on clinical status and meta-analysis of diagnosis and clinical management

Albakri¹

2018

Pediatr Dimensions

View full text Add to dashboard Cite

Restrictive cardiomyopathy is a myocardial disorder characterized by restrictive ventricular filling. It represents one of the three phenotypes originally classified by the World Health Organization besides dilated and hypertrophic cardiomyopathies. Of the three, it is the least common phenotype but has an ominous prognosis with the highest recorded rates of sudden cardiac death. Clinical trials investigating RCM have had varied findings. This is attributable to the current classification systems of cardiomyopathy based on morphological and structural alterations rather than etiologic-based. The classification has created etiological heterogeneity requiring a combination of methods for a confirmatory diagnosis as well as complicating clinical management methods, which lacks standardized guidelines and largely relies on the standard heart failure therapy. Thus, the present review discussed current research evidence to produce a comprehensive understanding of the clinical status of RCM, including its diagnosis and clinical management.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Status Of Prognosismentioning

confidence: 99%

Restrictive cardiomyopathy: A review of literature on clinical status and meta-analysis of diagnosis and clinical management

Albakri¹

2018

Pediatr Dimensions

View full text Add to dashboard Cite

show abstract

“…Destination therapy with ventricular assist devices may be a therapeutic option for patients as him. In summary, amyloidosis (16,17) has to be added to the list of differential diagnoses of graft failure in a heart transplant recipients. The diagnosis is difficult to obtain and needs to be verified e.g.…”

Section: Resultsmentioning

confidence: 99%

Cardiac amyloidosis in a heart transplant patient - A case report and retrospective analysis of amyloidosis evolution

Kintsler

Jäkel

Brandenburg

et al. 2015

IRDR

View full text Add to dashboard Cite

“…The average survival time of systemic amyloidosis is 12 to 15 months, and if involving the heart, the average survival time is less than five months [4].…”

Section: Discussionmentioning

confidence: 99%

18F-FDG-PET-CT with Little Value in Different Diagnosis between Pulmonary Malignancy and Amyloidosis

Song¹

2014

J Hematol Thrombo Dis

View full text Add to dashboard Cite

Pulmonary amyloidosis is rare and is often misdiagnosed due a lack of general awareness of the condition. The role of PET-CT in the differential diagnosis between pulmonary amyloidosis and lung malignant tumors is still unclear. Herein, we describe a 61-year-old Chinese woman who presented with a right lower lobe pulmonary nodule, and right hilar and mediastinal lymph nodes shadows. On PET-CT examination, the patient was found to have right lower lung malignant lesions with multiple right hilar and mediastinal lymph node metastases. She was diagnosed with nephrotic syndrome with a history of pathologic type of amyloidosis over the previous two months. After performing right thoracotomy, a histopathologic diagnosis of pulmonary amyloidosis was made. The patient has done well postoperatively, showing no local recurrence in the lung or deterioration of her condition in a 12-month follow-up period. The pathology of nephrotic syndrome in patients with amyloidosis led to the diagnosis of systemic amyloidosis being made in this patient. From this case, combined with the domestic and international literature, we conclude that PET-CT is of little value for the different diagnosis between pulmonary amyloidosis and lung malignant tumors.

show abstract

Current Trends in Diagnosis and Management of Cardiac Amyloidosis

Cited by 59 publications

References 99 publications

Restrictive cardiomyopathy: A review of literature on clinical status and meta-analysis of diagnosis and clinical management

Restrictive cardiomyopathy: A review of literature on clinical status and meta-analysis of diagnosis and clinical management

Cardiac amyloidosis in a heart transplant patient - A case report and retrospective analysis of amyloidosis evolution

18F-FDG-PET-CT with Little Value in Different Diagnosis between Pulmonary Malignancy and Amyloidosis

Contact Info

Product

Resources

About